Stock Taper Revenue: $866 million, flat year-over-year. Adjusted for supplemental payments from prior periods, revenue growth was 2.8%.
Adjusted EBITDA: $149.2 million. This includes a $26.1 million benefit from Florida supplemental payments and a $28.6 million increase in professional liability reserves, resulting in a net negative impact of $2.5 million.
Adjusted EPS: Not explicitly stated in the summary but guided to be between $1.45 and $1.60 for the full year.
Free Cash Flow: $124 million generated in Q2, with a net debt reduction of $113 million.
Operating Cash Flow: $162 million, with a revised full-year guidance of $350 million to $400 million.
Operational Focus: Emphasis on operational execution and patient care through existing and new facilities. Two new acute facilities opened in Q2, contributing to a total of over 300 new beds added in the first half of the year.
Same-Facility Revenue: Flat year-over-year, with a 0.8% increase in patient days offset by a 0.8% decrease in revenue per patient day.
Specialty Business: Revenue increased by $5 million sequentially, showing resilience despite challenges from Medicaid changes.
RTC Business: Strong revenue growth of 12% year-over-year driven by volume growth.
CTC Clinics: Revenue flat year-over-year, with ongoing efforts to enhance service offerings and patient experience.
Updated Guidance: Full-year revenue guidance revised to $3.4 billion to $3.45 billion, adjusted EBITDA of $590 million to $615 million, and operating cash flow of $350 million to $400 million.
Future Capacity: Anticipation of adding 500 to 600 beds in 2026, with a focus on ramping occupancy in new facilities.
EBITDA Growth: Confidence in achieving $200 million of incremental adjusted EBITDA from facilities opened between 2023 and 2026.
Revenue Growth: Overall revenue growth was flat, raising concerns about the sustainability of growth in a competitive market.
Professional Liability Reserves: Increased reserves due to higher case severity and frequency of claims, with a potential future impact on financials.
Regulatory Risks: Ongoing uncertainty regarding Medicaid work requirements and potential impacts on patient eligibility and revenue.
Labor Market: While currently stable, any shifts in labor availability or wage pressures could impact operational efficiency.
Operational Improvements: CEO Debbie Osteen emphasized the importance of having the right experienced team and operational discipline to drive performance.
Payer Relationships: Management expressed a commitment to collaborative relationships with payers, focusing on demonstrating clinical outcomes to improve negotiations.
Revenue Cycle Management: Progress noted in stabilizing bad debt and denials, with a proactive approach to addressing isolated issues in specific markets.
De Novo Facilities: Management highlighted improvements in ramping new facilities, with a focus on reducing approval times and enhancing operational efficiency.
Market Demand: Continued strong demand for services was noted, particularly in the context of opioid treatment and behavioral health care. Overall, Acadia Healthcare demonstrated solid operational performance in Q2 2026, with a focus on strategic growth and operational discipline, despite facing challenges in revenue growth and regulatory uncertainties.
SOURCE: Q2 2026 EARNINGS CALL TRANSCRIPT